Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Infants between 42 and 98 days of age (approximately 2 months) at the time of enrollment.~Exclusion Criteria:~* Previous vaccination with pneumococcal vaccine,Haemophilus influenzae type B (Hib) conjugate vaccine, meningococcal type C conjugate vaccine, or diphtheria, tetanus, pertussis, or poliovirus vaccines.~* Previous anaphylactic reaction or allergy to any vaccine~* Contraindication to vaccination~* Known or suspected immune deficiency or immune suppression~* Major known congenital malformation or serious chronic disorder~* Significant neurological disorder~* Participation to another study

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 98 Days
- Healthy Volunteers: f

Study Arms:
- Group 1: Preterm infants (Type: ACTIVE_COMPARATOR): Infant born at \< 37 weeks of gestation.
- Group 2: Term infants (Type: ACTIVE_COMPARATOR): Infants born at ≥ 37 weeks of gestation

Based on this trial design, predict the completion outcome and termination type (if applicable).